Celgene: Impact Biomedicines To Broaden The Pipeline

Celgene (CELG) has joined the M&A craze at the start of 2018 with the purchase of privately-held Impact Biomedicines. The deal is structured in a savvy way and boosts the pipeline of Celgene.

The deal announcement comes alongside the release of preliminary results for Q4, accompanied by a solid outlook for 2018. A modest valuation, full pipeline and strong financial position make that I am adding on the latest dip in the share price.

The Deal

Celgene has acquired Impact Biomedicines in a deal which involves a $1.1 billion upfront cash payment. With the deal Celgene is making a bet on drug candidate fedratinib which might be used to treat myelofibrosis and polycythemia vera.

READ FULL ARTICLE HERE

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.